Latent TB Infection (LTBI) Guideline Updates

Original Guideline
Title	Format
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection MMWR 2000; 49 (No. RR-6)	PDFpdf icon [350KB]

Updates
Title	Format
Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection MMWR 2003; 52 (No. 31).	PDFpdf icon [587KB]
Update: Fatal and Severe Liver Injuries Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection, and Revisions in American Thoracic Society/CDC Recommendations — United States, 2001. MMWR 2001; 50 (No. 34) (August 31, 2001)	PDFpdf icon [287KB]
Fatal and Severe Hepatitis Associated With Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection — New York and Georgia, 2000 MMWR 2001; 50 (No. 15) (April 20, 2001)	PDFpdf icon [338KB]

Archived Updates
Title
Background: Severe and Fatal Liver Injury Connected to Latent TB Treatment (August 30, 2001)

Page last reviewed: September 1, 2012